Protalix BioTherapeutics
PLX
32 hedge funds and large institutions have $1.29M invested in Protalix BioTherapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 7 closing their positions.
237% more call options, than puts
Call options by funds: $735K | Put options by funds: $218K
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
3% more funds holding
Funds holding: 31 → 32 (+1)
3.78% less ownership
Funds ownership: 6.45% → 2.67% (-3.8%)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
47% less capital invested
Capital invested by funds: $2.45M → $1.29M (-$1.16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$224K |
| 2 |
Jane Street
New York
|
+$54.6K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$26.4K |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$21.1K |
| 5 |
SSWM
Smith Salley Wealth Management
Greensboro,
North Carolina
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.16M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$548K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$64K |
| 4 |
Two Sigma Advisers
New York
|
-$37.6K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
TCWA
27
Ten Capital Wealth Advisors
Spokane,
Washington
| $1K | +$128 | +140 | +22% |
|
28
JP Morgan Chase
New York
| $1K | +$1.03K | +1,127 | New |
|
|
APA
29
American Portfolios Advisors
Holbrook,
New York
| $530 | +$458 | +500 | New |
|
|
30
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$33K | -40,290 | Closed |
|
31
Citadel Advisors
Miami,
Florida
| – | -$26.6K | -29,015 | Closed |
|
|
GCP
32
GSA Capital Partners
London,
United Kingdom
| – | -$20K | -24,527 | Closed |
|
|
CG
33
Cutler Group
San Francisco,
California
| – | -$8K | -10,067 | Closed |
|
|
MIFH
34
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
| – | -$2K | -2,432 | Closed |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$444 | -485 | -97% |
|
36
Citigroup
New York
| – | +$275 | +300 | New |
|
PLX Hedge Fund Activity: Q1 2022 in Review
32 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2022, worth a combined $1.29M — down 47% from $2.45M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PLX positions and 7 closed out — a net gain of 2 holders — while 5 added to existing stakes and 9 trimmed.
The largest buyer was Meitav Investment House, opening a new position worth an estimated $224K. The largest seller was Morgan Stanley, cutting an estimated $1.16M.
- 32 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2022, up from 31 in Q4 2021.
- Funds reported $1.29M of Protalix BioTherapeutics stock for Q1 2022, down 47% quarter-over-quarter.
- 9 funds opened new Protalix BioTherapeutics positions in Q1 2022 and 7 closed out, a net change of +2 holders.
- The largest Protalix BioTherapeutics buyer in Q1 2022 was Meitav Investment House, an estimated $224K added.
- The largest Protalix BioTherapeutics seller in Q1 2022 was Morgan Stanley, an estimated $1.16M sold.
Based on aggregated 13F filings for Q1 2022.